Google Übersetzer
Nanobiotix Sa
About
38.94EUR-3.78 -8.85%
Closed • Updated at 13:45 GMT+00:00Market Cap$2.41B
Volume264.2K
Beta0.48
RSI58.80
Nanobiotix Sa — investor relations, events, news, and company updates on 6ix.
Latest News
May 4 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
Apr 20 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Apr 7 2026
Voting Rights and Shares Capital of the Company
Mar 31 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Mar 30 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Recent Videos
NANOBIOTIX #investissementlongterme
Apr 21, 2026
Cómo comprar acciones de Nanobiotix SA (NANO.PA)
Apr 10, 2026
Le journal des biotechs : Laurent Levy (Nanobiotix), Jamila El Bougrini (Invest Securities)
Apr 08, 2026
Nanobiotix Q4 2025 Earnings Call | NBTXR3 Head and Neck Cancer Trial Milestone Reached
Apr 02, 2026